Literature DB >> 15289996

Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study.

Xiang Yang Zhang1, Dong Feng Zhou, Lian Yuan Cao, Pei Yan Zhang, Gui Ying Wu, Yu Cun Shen.   

Abstract

RATIONALE: There are few data from systematic, double-blind clinical trials that have compared the effect of the typical and the atypical antipsychotics on serum prolactin (PRL) levels in patients with schizophrenia.
OBJECTIVES: The goal of this study was to compare the effect of risperidone and haloperidol on serum PRL and investigate the relationship between serum PRL levels and clinical response in patients with schizophrenia.
METHODS: Seventy-eight inpatients with a diagnosis of schizophrenia (according to DSM-III-R) were randomly assigned to 12 weeks of treatment with 6 mg/day of risperidone or 20 mg/day of haloperidol after a 2-week washout period, using a randomized, double-blind design. Clinical efficacy was determined using the positive and negative syndrome scale (PANSS). Their serum PRL was assayed by means of radioimmunometric assay (RIA) between pre-treatment and post-treatment, and compared with 30 sex-matched and age-matched normal subjects.
RESULTS: Both risperidone and haloperidol treatment significantly increased serum PRL levels in drug-free chronic schizophrenia patients (both P<0.001). Hyperprolactinemia induced by risperidone 6 mg/kg was comparable to levels produced by haloperidol 20 mg/day. Considering dose-adjusted serum PRL levels, risperidone treatment induced a significant elevation of PRL levels compared with haloperidol treatment at the haloperidol equivalent (P<0.001). Change in PRL levels at pre-treatment and post-treatment were related to positive symptom improvement seen in the risperidone group (r=0.51, P=0.016), but not in the haloperidol group (P>0.05). Female patients showed both a higher baseline and post-treatment PRL level and a greater increase in PRL than men (all P<0.05).
CONCLUSIONS: Risperidone is associated with a robust effect on prolactin secretion in contrast to the conventional antipsychotic haloperidol. Prolactin monitoring during risperidone treatment should be performed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289996     DOI: 10.1007/s00213-004-1975-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  26 in total

Review 1.  Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.

Authors:  S Kapur; P Seeman
Journal:  Am J Psychiatry       Date:  2001-03       Impact factor: 18.112

2.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

3.  Prolactin levels and adverse events in patients treated with risperidone.

Authors:  D L Kleinberg; J M Davis; R de Coster; B Van Baelen; M Brecher
Journal:  J Clin Psychopharmacol       Date:  1999-02       Impact factor: 3.153

Review 4.  Towards more effective antipsychotic treatment.

Authors:  J M Kane; H L Freeman
Journal:  Br J Psychiatry Suppl       Date:  1994-11

5.  The effect of neuroleptics on serum prolactin in schizophrenic patients.

Authors:  H Y Meltzer; V S Fang
Journal:  Arch Gen Psychiatry       Date:  1976-03

6.  The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.

Authors:  S R David; C C Taylor; B J Kinon; A Breier
Journal:  Clin Ther       Date:  2000-09       Impact factor: 3.393

7.  Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone.

Authors:  M Markianos; J Hatzimanolis; L Lykouras
Journal:  Psychopharmacology (Berl)       Date:  2001-08       Impact factor: 4.530

8.  Impact of risperidone medication on quality of life and gonadal axis hormones in schizophrenia male patients with acute exacerbation.

Authors:  Yasuhiro Kaneda; Tetsuro Ohmori
Journal:  Int J Neuropsychopharmacol       Date:  2003-09       Impact factor: 5.176

9.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.

Authors:  L Farde; A L Nordström; F A Wiesel; S Pauli; C Halldin; G Sedvall
Journal:  Arch Gen Psychiatry       Date:  1992-07

Review 10.  Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects.

Authors:  U Halbreich; B J Kinon; J A Gilmore; L S Kahn
Journal:  Psychoneuroendocrinology       Date:  2003-01       Impact factor: 4.905

View more
  2 in total

Review 1.  Management of psychosis associated with a prolactinoma: case report and review of the literature.

Authors:  Shirin Ali; Karen Klahr Miller; Oliver Freudenreich
Journal:  Psychosomatics       Date:  2010 Sep-Oct       Impact factor: 2.386

Review 2.  Prolactin and psychopathology in schizophrenia: a literature review and reappraisal.

Authors:  Ravi Philip Rajkumar
Journal:  Schizophr Res Treatment       Date:  2014-03-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.